16
Table 6. Recommendations on Second-Line Systemic
Colorectal Metastatic Treatment
Note: is table pertains to Enhanced and Maximal settings, with
presumption of lack of chemotherapy in other settings.
Population Rec #
Received oxaliplatin in first line 3.1
Received irinotecan in first line 3.2
No bevacizumab in first line 3.3
Received bevacizumab in first line 3.4
RAS WT, received anti-EGFR in first line 3.5
BRAF V600E MUT 3.6
dMMR or MSI-high 3.7
Treatment
